Important life science current events reported by MedCity News this week.
5 mistakes companies make launching new drugs, medical devices. One major issue highlighted at a panel discussion at Biotech 2011 was the multitude of things that can go wrong when medical device and drug companies launch a product. Here are just a few of them. The lifespan of a drug or device can be decided in the first few months of its launch, several panelists noted.
Cleveland Clinic quits reporting infection data to patient safety group. Cleveland Clinic has stopped voluntarily reporting data on hospital-acquired infections to a prominent patient-safety nonprofit, The Leapfrog Group.
BioLabs Pegasus Park Cultivates Life Science Ecosystem
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
A healthcare Groupon? Gluten free tries deep discounts. A Minnesota entrepreneur is taking the the deep-discount group-purchasing business into consumer health in what he describes as the “gluten-free Groupon.”
Biotech 2011: Teva, Merck directors share views of biopharma industry. There were similar themes running through each man’s speech: Despite extending and improving people’s quality of life, the industry’s work is taken for granted and the regulatory and economic environment have slowed innovation in the industry or, at the very least, challenged it quite a bit, but there are ways to move forward.
Lifeline Ventures: The $100 million, one (anonymous) investor fund. LifeLine Ventures seems pretty much like any other venture capital fund except for one thing: the $100 million fund was sourced entirely from one investor. Not surprisingly, the Farmington Hills, Michigan-based fund’s managing director Ranjit Kommineni declined to identify that investor. (Kommineni is likely the envy of VCs everywhere for his one-stop fundraising.)
